Ensem Therapeutics Announces Dosing of First Patients in Phase 1/2 Clinical Trial of ETX-929, a Potential Best-in-Class Oral Pan-KRAS Inhibitor

On November 17, 2026 Ensem Therapeutics, Inc. (ENSEM), a clinical-stage, oncology-focused biopharmaceutical company, reported that the first patients have been dosed in its first-in-human Phase 1/2 clinical trial of ETX-929, a potent, oral, potential best-in-class pan-KRAS inhibitor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As one of the most frequently altered oncogenes across cancer types, KRAS represents a major opportunity for medical oncology, and KRAS G12C inhibitors have already become important therapies for patients with that one mutation," said Ron Peck, M.D., Chief Medical Officer of ENSEM. "By targeting the full range of KRAS alterations while sparing HRAS and NRAS, ETX-929 has the potential to deliver greater efficacy at doses patients can tolerate, building on the promise seen with early pan-RAS inhibitors."

"We designed ETX-929 to set a new standard among pan-KRAS inhibitors," said Shengfang Jin, Ph.D., President and Chief Executive Officer of ENSEM. "ETX-929 potently inhibits KRAS in both its active (ON) and inactive (OFF) states, across the major KRAS mutations as well as amplified wildtype KRAS. In preclinical studies, it showed a potential best-in-class profile compared with other pan-KRAS inhibitors, with sub-nanomolar in vivo potency, tumor regressions, and good oral bioavailability across species, including non-human primates, supporting low projected oral doses in patients. Following ETX-197 and ETX-636, ETX-929 is the third clinical candidate from our Kinetic Ensemble platform, and we hold global rights to all of our programs."

The first-in-human Phase 1/2 trial is an open-label, multicenter dose escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ETX-929 in patients with advanced KRAS-altered solid tumors, both as monotherapy and in combination with cetuximab, with the potential to add other combination cohorts in the future. The study is being conducted under an Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration (FDA). More information is available at www.clinicaltrials.gov under identifier NCT07912593.

About ETX-929

ETX-929 is a potent, oral, potential best-in-class pan-KRAS inhibitor discovered using ENSEM’s Kinetic Ensemble platform. It inhibits KRAS in both the active (ON) and inactive (OFF) states while sparing HRAS and NRAS and is designed to treat tumors with diverse KRAS mutations (G12X, G13X, Q61H) or wildtype KRAS amplification. Oncogenic KRAS alterations occur in approximately 23% of human cancers, and about 85% of them have no approved targeted therapy.

Preclinical data presented at the AACR (Free AACR Whitepaper) Annual Meeting 2026 showed sub-nanomolar in vivo potency, tumor regressions across colorectal, lung and gastric cancer models with KRAS G12D, G12V, G12C or wildtype amplification, enhanced activity in combination with cetuximab, and good oral bioavailability across species, which supports the projected low oral doses in patients.

(Press release, ENSEM Therapeutics, NOV 17, 2026, View Source [SID1234674833])

Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors

On November 17, 2026 Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing Multispecific therapeutics in oncology, reported the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.

"Submission of the IND for ISB 2301 marks an important milestone in advancing IGI’s multispecific oncology pipeline into clinical development," said Lida Pacaud, M.D., President and Chief Executive Officer, IGI. "This pentaspecific candidate is designed to integrate multiple tumor-targeting and immune-engaging functions within a single molecule. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, a candidate we believe to be highly differentiated from current approaches. We plan to initiate a Phase 1 clinical trial of ISB 2301 in patients with solid tumors in 2027."

ISB 2301 was engineered using IGI’s proprietary BEAT Multispecific Platform and is designed to recognize three tumor-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.

In preclinical studies, ISB 2301 demonstrated favorable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned evaluation of its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity in patients with advanced solid tumors.

(Press release, Ichnos Sciences, NOV 17, 2026, View Source;utm_medium=rss&utm_campaign=ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in-class-multispecific-immune-cell-activator-targeting-solid-tumors [SID1234674879])

CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics

On November 17, 2026 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron, triggering a $5 million milestone payment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Regeneron and CytomX collaboration agreement combines CytomX’s PROBODY therapeutic masking technology with Regeneron’s Veloci-Bi bispecific antibody platform to develop bispecifics that remain inactive within systemic circulation until activated by proteases highly enriched in the tumor microenvironment. This approach has the potential to broaden the therapeutic window and minimize off-target side effects for next-generation T-cell engaging therapies.

"Achievement of this first milestone from our Regeneron partnership represents the translation of promising science towards the clinic and underscores the potential synergistic approach of combining our respective technologies. Following the expansion of our collaboration in June 2026, we are excited to advance our aligned vision of bringing highly innovative new treatment options to cancer patients," said Sean McCarthy, D. Phil, CEO and Chairman of CytomX.

(Press release, CytomX Therapeutics, NOV 17, 2026, View Source [SID1234674898])

City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer

On November 17, 2026 City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, and Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, reported the launch of an innovative Phase 1 clinical trial to explore a new combination therapy for patients battling metastatic colorectal cancer, particularly for those whose disease has resisted standard treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Colorectal cancer is the second deadliest cancer in the U.S., and current treatments don’t work for everyone. We urgently need to find new options, especially for the advanced stages of this challenging disease," said principal investigator Marwan G. Fakih, M.D., a City of Hope professor in the Department of Medical Oncology & Therapeutics Research and deputy director of City of Hope Comprehensive Cancer Center.

This year alone, an estimated 159,000 Americans will be diagnosed with colorectal cancer, and the disease will claim about 55,230 lives, according to the American Cancer Society.

City of Hope’s trial will enroll up to 36 patients to evaluate two experimental drugs, ivonescimab and muzastotug (ADG126)*, in the treatment of advanced microsatellite stable colorectal cancer. Ivonescimab activates the immune system’s T cells to attack cancer cells as it cuts off the blood supply to tumors, while ADG126 enhances the immune system’s ability to recognize and destroy cancer. The two drugs are expected to result in synergistic antitumor activity.

"Based on insights gleaned from past studies, we expect this powerful drug combination will result in more potent activation of the immune system within tumors, leading to potential tumor regression or death," Dr. Fakih said. "Our mission is to speed lifesaving care to patients by crafting a more effective therapy that enhances quality of life and boosts survival rates."

Physician-led innovation to reshape patient care

Investigator-initiated trials like this one are clinical studies designed by doctors or scientists rather than an industry sponsor. Fueled by researchers’ scientific curiosity, medical insight and dedication to patient-centered care, these trials provide independent, real-world data that can ignite therapeutic advances and shift clinical guidelines.

Dr. Fakih and his colleagues will initially evaluate the combination of ivonescimab and ADG126 in patients who progressed on prior systemic therapy and will determine the most optimal dosing combination based on safety and efficacy. Once the optimal dose is identified, they plan to move this combination earlier on in the treatment of metastatic colorectal cancer. Specifically, they will explore combining this immunotherapy combination with 5-FU, the backbone of chemotherapy treatments in colorectal cancer. Subsequently, they will add an additional chemotherapy drug, irinotecan, which is commonly used in the first-line and second-line treatment of metastatic colorectal cancer.

"We hope that the combination of immunotherapy with ivonescimab and ADG126 will work hand in hand with chemotherapy to improve further tumor shrinkage in advanced colorectal cancer," Dr. Fakih said. "The combination of ivonescimab, ADG126 and 5-FU has the potential to serve as a more effective maintenance therapy in metastatic colorectal cancer, deepening and maintaining responses to therapy. The combination of ivonescimab, ADG126, 5-FU and irinotecan has the potential to serve as a first-line treatment in metastatic colorectal cancer and improve further on the chances of remission, regression and duration of disease control."

Peter Luo, Ph.D., chairman, CEO and president of R&D at Adagene, added, "This is the third clinical program to combine muzastotug or ADG126 with a next generation PD-1 bispecific with the goal of driving additional survival benefit for patients. This trial further validates and broadens the potential use of ADG126 as a foundational combination backbone to potentially drive more clinically meaningful survival benefits for patients.

"ADG126 is designed to activate preferentially in the tumor microenvironment, enabling CTLA-4 blockade while limiting on-target, off-tumor activity in healthy tissues. By combining this approach with complementary immune, angiogenic and cytotoxic mechanisms, the study will assess the safety and preliminary antitumor activity of these regimens. We value City of Hope’s leadership and clinical expertise in colorectal cancer."

Fighting a high risk of recurrence

Some 85% of colorectal cancer cases are classified as microsatellite stable (MSS), which has a higher risk of returning after treatment. Despite numerous clinical studies, no new therapies have outperformed existing treatments in halting growth.

Recent findings, however, have suggested promising new directions, including:

Integrating ivonescimab and chemotherapy significantly improved results in a small trial of 22 people, with 82% of the patients responding positively.
Blending two treatments — one targeting a protein called PD-1 and another targeting blood vessel growth (VEGFR) — helped patients whose colorectal cancer had not spread to the liver.
Ivonescimab targets both PD-1 and VEGF, potentially enhancing effectiveness while reducing side effects. When paired with drugs that block PD-1, ADG126 boosted the immune system’s ability to combat cancer.
Building off these discoveries, Dr. Fakih and his team developed the current trial to investigate how combining ivonescimab and ADG126 affects patients with advanced colorectal cancer.

In integrating the approach with traditional chemotherapy, his work aims to pinpoint the safest dosage for new drug combinations and determine how long they combat cancer growth.

"The clock is ticking; we can’t afford to lose more patients to this devastating disease," Dr. Fakih said. "Our study is a crucial step forward in finding better approaches for fighting advanced colorectal cancer."

(Press release, City of Hope, NOV 17, 2026, View Source [SID1234674834])

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

On November 17, 2026 Karyopharm Therapeutics Inc. (OTC Pink: KPTIQ) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis. The Prescription Drug User Fee Act (PDUFA) target action date is June 28, 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"FDA acceptance of our sNDA is a significant milestone in the development of selinexor for patients with myelofibrosis and marks an important step toward expanding selinexor’s impact and reach," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "I want to thank our employees for their persistence, dedication and extraordinary commitment which have brought us to this milestone. Building on our established commercial experience, our teams are actively preparing for a potential launch, with a goal of bringing selinexor plus ruxolitinib to myelofibrosis patients as quickly as possible, if approved."

"Myelofibrosis patients continue to face a significant unmet need, with JAK inhibitors as the only approved class of therapy," said Reshma Rangwala, M.D., Ph.D., Chief Medical Officer and Head of Research of Karyopharm. "Selinexor offers a differentiated mechanism of action and, if approved, selinexor plus ruxolitinib could become the first approved combination therapy for patients with myelofibrosis. We look forward to working with the FDA throughout the review process to advance a potential selinexor combination to patients with myelofibrosis."

The sNDA is primarily based on results from the Phase 3 SENTRY trial that were presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and were simultaneously published in the peer-reviewed Journal of Clinical Oncology. In addition, the results were presented at the 2026 European Hematology Association (EHA) (Free EHA Whitepaper) Congress, where the presentation was recognized as one of the six best abstracts at the meeting.

About the Phase 3 SENTRY Trial

SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction ≥ 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline.

About Myelofibrosis

Myelofibrosis is a rare blood cancer that affects approximately 20,000 patients in the United States and 19,000 patients in the European Union1. The disease causes bone marrow fibrosis (scarring in the bone marrow), which makes it difficult for the bone marrow to make healthy blood cells, splenomegaly (enlarged spleen), progressive anemia which often leads to symptoms like fatigue and weakness, and other disease associated symptoms including abdominal discomfort, pain under the left ribs, early satiety, night sweats and bone pain. The only approved class of therapies to treat myelofibrosis are JAK inhibitors, including ruxolitinib.

1. Clarivate/DRG (2023)

About XPOVIO (selinexor)

XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm’s partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high-unmet need cancer indications.

For more information about Karyopharm’s products or clinical trials, please contact the Medical Information department at: Tel: +1 (888) 209-9326; Email: [email protected]

XPOVIO (selinexor) is a prescription medicine approved:

In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd).
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).
SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care.
Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony‐stimulating factors.
Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care.
Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care.
Serious Infection: Monitor for infection and treat promptly.
Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes.
Embryo‐Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception.
Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract.

Adverse Reactions

The most common adverse reactions (≥20%) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3‐4 laboratory abnormalities (≥10%) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia, and neutropenia. In the BOSTON trial, fatal adverse reactions occurred in 6% of patients within 30 days of last treatment. Serious adverse reactions occurred in 52% of patients. Treatment discontinuation rate due to adverse reactions was 19%.
The most common adverse reactions (≥20%) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in 9% of patients. Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%.
Use In Specific Populations
Lactation: Advise not to breastfeed.

(Press release, Karyopharm, NOV 17, 2026, View Source [SID1234674880])